Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tanswell

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Biopharmaceutics & Drug Disposition|April 9, 1998
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical modelsK R Godfrey, P Tanswell, R A Bates, et al.
Journal of the American College of Cardiology|April 1, 1992
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarctionP Tanswell, U Tebbe, K L Neuhaus, et al.
The American Journal of Cardiology|September 1, 1989
Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarctionU Tebbe, P Tanswell, E Seifried, et al.
Arzneimittel-Forschung|March 1, 1988
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteersE Seifried, P Tanswell, D C Rijken, et al.
Investigational New Drugs|January 7, 2004
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patientsC Kloft, E-U Graefe, P Tanswell, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
Thrombosis and Haemostasis|October 22, 1990
Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patientsB R Reed, A B Chen, P Tanswell, et al.
Onkologie|March 8, 2003
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancerR-D Hofheinz, S-E al-Batran, F Hartmann, et al.
Journal of the American College of Cardiology|December 31, 1997
Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarctionD C Gulba, P Tanswell, R Dechend, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsP Tanswell, P Garin-Chesa, W J Rettig, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Biopharmaceutics & Drug Disposition|April 9, 1998
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical modelsK R Godfrey, P Tanswell, R A Bates, et al.
Journal of the American College of Cardiology|April 1, 1992
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarctionP Tanswell, U Tebbe, K L Neuhaus, et al.
The American Journal of Cardiology|September 1, 1989
Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarctionU Tebbe, P Tanswell, E Seifried, et al.
Arzneimittel-Forschung|March 1, 1988
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteersE Seifried, P Tanswell, D C Rijken, et al.
Investigational New Drugs|January 7, 2004
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patientsC Kloft, E-U Graefe, P Tanswell, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
Thrombosis and Haemostasis|October 22, 1990
Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patientsB R Reed, A B Chen, P Tanswell, et al.
Onkologie|March 8, 2003
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancerR-D Hofheinz, S-E al-Batran, F Hartmann, et al.
Journal of the American College of Cardiology|December 31, 1997
Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarctionD C Gulba, P Tanswell, R Dechend, et al.
British Journal of Clinical Pharmacology|March 22, 2001
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsP Tanswell, P Garin-Chesa, W J Rettig, et al.
Pageof 4